This was the stock's second consecutive day of gains.

This was the stock's second consecutive day of gains.

FIRDAPSE boosts Catalyst's strong Q1 2025 results, beating forecasts. With 15–20% growth projected, see why analysts rate ...

Catalyst Pharmaceuticals reported a robust start to 2025 with earnings per share (EPS) of $0.68, doubling the forecast of $0.34. Revenue reached $141.4 million, surpassing expectations of $131.54 ...

Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.

As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. To get the accrual ratio we first ...

CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2025 and ...

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) reported a 43.6% year-over-year increase in total net revenues, reaching $141.4 million. The company maintains a strong cash position of $580.7 million ...

Good day everyone, and welcome to the Catalyst Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator ...

Catalyst Pharmaceuticals CPRX reported adjusted earnings of 68 cents per share for the first quarter of 2025, beating the Zacks Consensus Estimate of 53 cents. The company had recorded adjusted ...